Gmax Biopharm LLC

Alibaba Group Holding Limited

Gmaz Biopharm LLC

Hangzhou Enmu Trade Co., Ltd.

Xiaofeng Wang

Hua Zhang

Cheng Zhang

Shuqian Jing

Chenjiang Yao

Yan Jiang

Min Wang

Xinxin Shi

Hao Pan

Lizhong Li

Yang Yu

Daocheng Xie

Rongzhu Wang

Lei Sun

Hui Dong

Weiqin Wan

Liangliang Bi

Switch

Provided herein are an apelin receptor (APJ) antibody and its fusion protein with Elabela. Also provided herein is a pharmaceutical composition of a fusion protein with APJ antibody and Elabela, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension or one or more symptoms of heart failure.

APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01

Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.

GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof

The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Human endothelin receptor antibody and use thereof

Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.

GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof

A user identity verification method is disclosed. The method includes receiving an identity verification request sent by a user through a client terminal; determining a user communication number according to the identity verification request and generating a corresponding temporary communication number for the user communication number; recording the user communication number and the temporary communication number as first data; returning the temporary communication number to the client terminal; receiving a call request initiated by the user to the temporary communication number; determining a respective user communication number and a respective temporary communication number corresponding to the call request as second data; verifying whether the first data matches with the second data; and returning a verification result to the client terminal. The method can improve security and reliability of identity verification, reduce a user's waiting time, and enhance user experience.

User identity verification method and system, and verification server

Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.

Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1

Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1

Growing community of inventors

Hangzhou, China

Xiaofeng Wang